Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment.
Ao W, Kim HI, Tommarello D, Conrads KA, Hood BL, Litzi T, Abulez T, Teng PN, Dalgard CL, Zhang X, Wilkerson MD, Darcy KM, Tarney CM, Phippen NT, Bakkenist CJ, Maxwell GL, Conrads TP, Risinger JI, Bateman NW.
Ao W, et al. Among authors: bakkenist cj.
Gynecol Oncol. 2023 Oct;177:60-71. doi: 10.1016/j.ygyno.2023.08.004. Epub 2023 Aug 26.
Gynecol Oncol. 2023.
PMID: 37639904